WuXi AppTec

2025.09.05

16:10

Hong Kong Stock Market Close Review: Hang Seng Index rose 1.43%, Hang Seng Tech Index rose 1.95%

At the close of Hong Kong trading, the Hang Seng Index rose 1.43%, while the Hang Seng Tech Index rose 1.95%. The Hong Kong Tech ETF (159751) rose 2.5%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose 1.54%. Among sectors, biotechnology and semiconductor products and equipment led the gains. In terms of individual stocks, Horizon Robotics-W rose 9.12%, Kelun Botai Bio-B rose 6.63%, China Biologic Products rose 6.2%, China Aluminum Corporation rose 6.12%, Hengrui Medicine rose 5.96%, Shandong Gold rose 5.87%, Zijin Mining rose 5.85%, Luoyang Molybdenum Co., Ltd. rose 5.77%, China Hongqiao rose 5.14%, Kangfang Biopharmaceuticals rose 5.09%, SMIC rose 4.82%, WuXi Biologics rose 4.71%, Hansoh Pharmaceutical rose 4.56%, Zhaojin Mining rose 4.44%, Kuaishou-W rose 4.36%, WuXi AppTec rose 4.22%; Gemdale Properties fell 4.49%, Uni-President Enterprises China fell 4.62%; China Innovation Aviation rose 18.37%, and Sansure Pharmaceutical rose 18.24%.

16:10

At the close of Hong Kong stocks, the Hang Seng Index rose 1.43%, and the Tech Index rose 1.95%. Horizon Robotics (09660.HK) rose over 9%, while WuXi AppTec (02359.HK) and Kuaishou (01024.HK) rose over 4%.

14:27

The A-share innovative drug sector continued to rise, with Zejing Pharmaceutical rising more than 15%, Sunbet Biotech and Haichen Pharmaceutical rising more than 11%, Borrui Pharmaceutical and Zhaoyan Pharmaceutical rising more than 9%, and Changchun High-Tech, Junshi Biosciences, and WuXi AppTec following suit.

2025.09.04

13:37

The A-share pharmaceutical and biological sector fluctuated downward, with Sanyou Medical falling more than 13%, WuXi AppTec and Biologics falling more than 9%, and Maiwei Biopharmaceuticals and Nanxin Pharmaceutical falling more than 8%.

10:31

Hong Kong-listed innovative drug concept stocks fell collectively, with Zai Lab (09688.HK) down more than 11%, Hengrui Medicine (01276.HK), Ascletis Pharma (01672.HK), and Everest Medicines (01952.HK) down more than 5%, WuXi AppTec (02359.HK) down more than 4%, Innovent Biologics (01801.HK), WuXi Partners (02268.HK), and Hansoh Pharmaceutical (03692.HK) down more than 3%.

2025.09.02

17:23

WuXi AppTec: Subsidiary equity transferred to a newly established wholly-owned subsidiary

WuXi AppTec announced plans to transfer its 98.9% stake in Shanghai Hequan Pharmaceuticals, held by Shanghai WuXi, to WuXi AppTec (Shanghai) Pharmaceutical Research & Development Co., Ltd. Upon completion of this equity transfer, WuXi Research & Development will directly hold 98.9% of the target company's shares. This equity transfer will not affect the scope of the company's consolidated financial statements, the substantive operations of the target company, or its profits or overall equity.

17:23

WuXi AppTec: Signed a Supplemental Agreement to the Payload Connector Master Services Framework Agreement with its Affiliate XDC Cayman

WuXi AppTec announced that it has signed a Supplemental Agreement to the Payload Connectivity Sub-Master Services Framework Agreement with its related party, XDC Cayman, increasing the 2025 related-party transaction limit from 168 million yuan to 200 million yuan. Additionally, the company and XDC Cayman signed a new three-year Payload Connectivity Sub-Master Services Framework Agreement, effective from January 1, 2026, to December 31, 2028. The annual transaction amounts for 2026, 2027, and 2028 are expected to be no more than 300 million yuan, 400 million yuan, and 400 million yuan, respectively. The company stated that this transaction is a normal commercial arrangement in its daily operations and will not affect its independence.

09:57

Hong Kong-listed biopharmaceutical stocks collectively strengthened, with BeiGene (06160.HK) rising more than 6%, Tiger Pharmaceuticals (03347.HK) and WuXi Biologics (02268.HK) rising more than 3%, and WuXi Biologics (02269.HK) and WuXi AppTec (02359.HK) rising more than 2%.

2025.09.01

16:10

Hong Kong Stock Market Close: Hang Seng Index rose 2.15%, Hang Seng Tech Index rose 2.2%, Alibaba-W rose 18.5%

At the close of Hong Kong trading, the Hang Seng Index rose 2.15%, while the Hang Seng Tech Index rose 2.2%. The Hong Kong Tech ETF (159751) rose 1.75%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose 1.53%. Among sectors, metals & mining and hotel & resort REITs led the gains, while aerospace & defense and leisure equipment & supplies led the declines. In terms of individual stocks, Alibaba-W rose 18.5%, Alibaba-WR rose 18.08%, CSPC Pharmaceutical Group rose 9.14%, Innovent Biologics rose 8.83%, WuXi Biologics rose 8.37%, Zijin Mining rose 7.74%, WuXi AppTec rose 7.51%, Kelun Biotech-B rose 7.0%, Shandong Gold rose 6.95%, Luoyang Molybdenum Co., Ltd. rose 6.73%, BOC (Hong Kong) rose 6.7%, BOC (Hong Kong)-R rose 6.27%, Sinopharm rose 6.17%, BeiGene rose 5.59%, SMIC rose 4.86%, NIO-SW rose 4.64%, Smoore International rose 4.39%, Hengrui Medicine rose 4.33%; Minth Group fell 7.91%, Meitu fell 13.88%; MicroPort Medical rose 21.96%.

14:35

WuXi AppTec's transaction volume reached 10 billion yuan

WuXi AppTec's transaction volume reached 10 billion yuan, and it is now up 7.56%.

13:07

Hong Kong stocks of innovative drug concepts continued to strengthen in the afternoon, with Innovent Biologics (01801.HK) rising more than 8%, Jingtai Holdings (02228.HK) rising more than 7%, WuXi Biologics (02269.HK) and WuXi AppTec (02359.HK) rising nearly 7%, and CSPC Pharmaceutical Group (01093.HK) rising nearly 6%.

13:05

Hong Kong-listed pharmaceutical stocks continued to rise in the afternoon, with CASI Biopharma-B rising over 20%.

Hong Kong-listed pharmaceutical stocks continued to rise in the afternoon, with CASI Biopharma-B rising more than 20%, Clover Biopharmaceuticals-B, Beihai Kangcheng-B, and Sinopharm-B rising more than 10%, Innovent Biologics rising more than 8%, and WuXi AppTec rising more than 6%.

12:02

Hong Kong Stock Market Midday Review: Hang Seng Index rose 1.77%, Hang Seng Tech Index rose 1.77%

At the midday close of Hong Kong stocks, the Hang Seng Index rose 1.77%, while the Hang Seng Tech Index rose 1.77%. The Hong Kong Tech ETF (159751) rose 1.67%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose 1.09%. Among sectors, healthcare technology and pharmaceuticals led the gains, while aerospace & defense and leisure equipment & supplies led the declines. In terms of individual stocks, Alibaba-W rose 17.29%, Alibaba-WR rose 16.67%, Innovent Biologics rose 9.04%, BOC (Hong Kong) rose 6.08%, BOC (Hong Kong)-R rose 6.03%, Zijin Mining rose 5.86%, WuXi Biologics rose 5.84%, WuXi AppTec rose 5.84%, Shandong Gold rose 5.79%, Smoore International rose 5.61%, CSPC Pharmaceutical Group rose 5.07%, SMIC rose 4.94%, Kelun Biotech-B rose 4.71%, BeiGene rose 4.45%, and ZTE rose 4.23%; BYD Co., Ltd. fell 6.82%, Meitu fell 12.18%; Melco International Development rose 18.76%.

10:04

Most of the Hong Kong stocks in the innovative drug sector rose, with WuXi Biologics (02269.HK) rising more than 5%, WuXi AppTec (02359.HK) rising more than 4%, BeiGene (06160.HK) and CSPC Pharmaceutical Group (01093.HK) rising nearly 4%.

2025.08.29

17:58

According to Hong Kong Stock Exchange documents, on August 25, BlackRock reduced its long position in WuXi AppTec (02359.HK) H shares from 5.46% to 4.88%.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Qualcomm (QCOM.O) CEO: Qualcomm needs more energy-efficient chips.
                            2025-09-06

                                    Jefferies: Raised Alibaba (BABA.N) price target from $150.00 to $165.00.
                            2025-09-01

                                    The statement showed that Alibaba and Bosch announced the deepening of their strategic partnership.
                            2025-09-02

                                    The value of projects signed at the 2025 Smart Expo exceeds 200 billion yuan
                            2025-09-05

                                    Challenger Gray, a US employment consulting firm, reports that pharmaceutical companies announced plans to lay off 19,112 employees in August, bringing the total to 22,433. This represents a 142% increase compared to the 9,254 layoffs reported in the same period last year. The industry is facing increasing competition from patent expirations and is refocusing on higher-margin products. Many companies are also implementing artificial intelligence, which is leading to restructuring and job losses.
                            2025-09-04